Adrestia Therapeutics
Adrestia Therapeutics is a UK-based, private biotech founded in 2017 that develops therapeutics to restore biological balance in damaged, diseased or dying cells. It operates as a discovery-stage company funded primarily by Ahren Innovation Capital and GlaxoSmithKline.
- Company typePrivate
- Founded2017
- HeadquartersBabraham, United Kingdom
- Headcount11–50
- GTM typeB2B
- OfferingServices
Adrestia Therapeutics firmographics
Firmographics- Name
- Adrestia Therapeutics
- Website
- https://adrestia.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Closed
- Headcount range
- 11–50 employees
- Short description
- Adrestia Therapeutics is a UK-based, private biotech founded in 2017 that develops therapeutics to restore biological balance in damaged, diseased or dying cells. It operates as a discovery-stage company funded primarily by Ahren Innovation Capital and GlaxoSmithKline.
- Ownership category
- akta.pro rank
Adrestia Therapeutics industry classification
Industry- Product category
- Biopharmaceutical Therapeutics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Therapeutic Enzymes & Enzyme Replacement Therapies (ERT) (HLAAAAAK)
Keywords
Where Adrestia Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Babraham
- HQ country
- United Kingdom
- HQ region
- Europe
Markets served
Adrestia Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure
Adrestia Therapeutics product offering
Product offeringCore offering
Adrestia Therapeutics is developing therapeutics that work in an entirely new way by restoring the biological balance in damaged, diseased, or dying cells. The company operates as a pre-commercial biopharmaceutical R&D entity focused on a proprietary cell-balance restoration approach to treat disease. It has not yet commercialized any named therapeutic product.
Differentiator
Problem solved
Functional benefit
Companies that use Adrestia Therapeutics
Customer profileIdeal customer profiles2 records
Adrestia Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Adrestia Therapeutics competitors and assessment
Company assessmentEmerging players
- Plexium: Emerging biotech using targeted protein degradation to modulate cell-health pathways — partial overlap in the 'restore cellular function' therapeutic paradigm.
- Tessellate Bio: Early-stage European biotech focused on novel targets in DDR and cancer cell fitness — comparable emerging platform with overlapping cell-health mechanism.
Others
- Ahren Innovation Capital: Lead investor in Adrestia's 2020 Series A; an early-stage science-led fund active across UK biotech — relevant ecosystem participant for comparable deal flow.
Broad incumbents
- AstraZeneca: Cambridge-headquartered global pharma with significant DDR / oncology pipeline (e.g., Lynparza, DDR portfolio) — incumbent operating in the same biological space as Adrestia.
- GlaxoSmithKline (SR One / GSK Ventures): A lead investor in Adrestia's Series A and a global pharma with multiple DDR/cell-biology programs — relevant as a commercial partner and broader comparator for valuation.
Direct peers
- Artios Bio: UK-based oncology biotech developing DDR (DNA damage response) therapeutics — directly comparable mechanism and UK/Cambridge-adjacent ecosystem to Adrestia.
- Repare Therapeutics: Clinical-stage precision oncology company developing synthetic lethality / DDR-targeted therapeutics — same broad DDR-and-genome-stability therapeutic angle as Adrestia.
- FoRx Therapeutics: Europe-based biotech developing DNA damage response therapeutics for cancer — closely comparable platform thesis and early-stage profile.
- Mission Therapeutics: UK-based biotech developing small-molecule therapeutics targeting DNA damage response enzymes (deubiquitinases) — same DDR-mechanism category and UK geography.
- Blacksmith Medicines: Biotech developing metalloenzyme-targeted therapeutics with a strong presence in genome-stability and cell-health pathways relevant to Adrestia's biology.
Market position
Customer concentration
Adrestia Therapeutics social profiles
Digital presenceAdrestia Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Adrestia Therapeutics leadership team
Management profileNumber of profiles
Profiles5 records
Adrestia Therapeutics funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Adrestia Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Adrestia Therapeutics
What does Adrestia Therapeutics do?
Adrestia Therapeutics is developing therapeutics that work in an entirely new way by restoring the biological balance in damaged, diseased, or dying cells. The company operates as a pre-commercial biopharmaceutical R&D entity focused on a proprietary cell-balance restoration approach to treat disease. It has not yet commercialized any named therapeutic product.
When was Adrestia Therapeutics founded?
Adrestia Therapeutics was founded in 2017. It employs 11 to 50 people.
Where is Adrestia Therapeutics based?
Adrestia Therapeutics is headquartered in Babraham, United Kingdom, in the Europe region.
Who are Adrestia Therapeutics's main competitors?
Emerging players on record are Plexium and Tessellate Bio. Ahren Innovation Capital is listed as an others. Broad incumbents are AstraZeneca and GlaxoSmithKline (SR One / GSK Ventures). Direct peers are Artios Bio, Repare Therapeutics, FoRx Therapeutics, Mission Therapeutics and Blacksmith Medicines.
Does Adrestia Therapeutics have an API?
No public API is recorded for Adrestia Therapeutics.
What industry is Adrestia Therapeutics in?
Adrestia Therapeutics's product category is Biopharmaceutical Therapeutics. Its primary akta.pro industry code is HLAAAAAK, Therapeutic Enzymes & Enzyme Replacement Therapies (ERT). Its NAICS code is 541714 and its SIC code is 8731.